KAI1 is a potential target for anti-metastasis in pancreatic cancer cells

Table 1 Invasive ability of pancreatic cancer cells (mean ± SD)

Cell type	Number of cells at different times
	10 h	20 h	30 h	40 h	50 h	60 h
MiaPaca II	20.6 ± 6.43	23.6 ± 7.50	43.6 ± 9.42	59.8 ± 6.06	86.8 ± 4.32	117.4 ± 4.88
pCMV-MiaPaca II	21.0 ± 7.21	24.8 ± 6.46	44.8 ± 8.56	62.6 ± 3.11	87.4 ± 1.82	115.4 ± 3.58
pCMV-KAI1-MiaPaca II	14.8 ± 6.69	16.4 ± 4.51	22.0 ± 4.69	25.6 ± 5.55	29.4 ± 4.93	33.6 ± 6.11
	P > 0.05	P > 0.05	P < 0.05	P < 0.05	P < 0.05	P < 0.05

P < 0.05 between KAI1-transfected and non-transfected cells.

Table 2 Effect of KAI1 expression on in vivo tumor growth (mean ± SD)

	Group	n	Tumor volume (cm3)	t	P
	Control	6	4.61 ± 1.98	-	-
A	KAI1-LipofectAMINE	6	1.22 ± 0.31	2.860	< 0.05
	pCMV-KAI1	6	1.67 ± 0.81	2.414	< 0.05
	Control	6	4.61 ± 1.98	-	-
B	KAI1-LipofectAMINE	6	4.87 ± 1.58	0.199	> 0.05
	pCMV-KAI1	6	4.16 ± 2.81	0.286	> 0.05

P < 0.05 between KAI1 transfection and controls.

Table 3 Analyses of liver and lung metastases with and without KAI1 transfection in mice in vivo (mean ± SD)

	Group	n	Liver weight (g)	t	P	Lung weight (g)	t	P
	Control	6	1.62 ± 0.39			0.45 ± 0.09
A	KAI1-LipofectAMINE	6	0.99 ± 0.21	2.661	< 0.05	0.30 ± 0.09	3.181	< 0.05
	pCMV-KAI1	6	1.01 ± 0.27	2.295	< 0.05	0.33 ± 0.09	2.291	< 0.05
	Control	6	1.62 ± 0.39			0.45 ± 0.09
B	KAI1-LipofectAMINE	6	1.69 ± 0.17	0.312	> 0.05	0.38 ± 0.03	1.348	> 0.05
	pCMV-KAI1	6	1.46 ± 0.28	1.286	> 0.05	0.36 ± 0.04	1.956	> 0.05

P < 0.05 between KAI1 transfection and controls.